Summer Sale
50% off Premium Yearly
Opinions Peter Hodson
Knight TherapeuticsGUD.TOCOMMENTApr 15, 2015
Stock price when the opinion was issued
As of Jun 19, 2026. Market Open.
You might be interested:
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Although the stock has not moved, the basic thesis has not changed. There is some weakness in South America which has impacted their acquisition. With no dividend, there is an opportunity cost to the stock, but outlook remains intact. Unlock Premium - Try 5i Free
Stockchase Insights
James Hodgins
Ryan ModestoHis biggest holding. They have $6.85 in tangible book value, mostly cash. The CEO may buy Paladin or Cipher Pharmaceuticals. Be patient for this deal. It'll be accretive.
James Hodgins
The biotech sector is on fire. You can’t open a newspaper without seeing a new takeover each day. This is the management team from Paladin Labs. They sold that and spun out this company and then went out and raised a lot of money through shareholders. Have now started to acquire products. This company needs a 5 year timeframe. From a management view in healthcare, he would rather bet on this management team that almost anybody else in Canada. Put it to bed for 5 years and you should be alright.